EUVIMEDEUVIMED entdecken
Crossref

Endoscopic Sleeve Gastroplasty Versus Oral Semaglutide for Obesity: A Real-World Comparative Study

N Jagtap, G Aman, A Katrevula, A Shujaath, D N Reddy, R Kalapala

Endoscopy · 01.06.2026 · 58 (S 03 S 03) · S96-S97

DOI: 10.1055/s-0046-1820792 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endoscopy, erschienen am 01.06.2026. Verfasst von N Jagtap und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Endoscopic sleeve gastroplasty (ESG) and glucagon-like peptide-1 receptor agonists are established therapies for obesity. However, comparative real-world data—especially with oral semaglutide—remain limited. We compared the short-term effectiveness and safety of ESG versus oral semaglutide 14 mg in obesity.

Methods

We conducted a retrospective comparative cohort study between January 2024 and April 2025. Adults aged 18–65 years with BMI≥30 kg/m² or≥27 kg/m² with obesity-related comorbidity treated with either ESG or oral semaglutide 14 mg daily and having 6-month follow-up were included. Primary endpoint was percentage total body weight loss (%TBWL) at 6 months. Secondary outcomes included responder rates (≥5%,≥10%,≥15% TBWL) and adverse events. Analyses included unadjusted t-tests, ANCOVA adjusted for age, sex, baseline BMI and diabetes, inverse probability of treatment weighting (IPTW), and 1:1 propensity-matched sensitivity analysis. Risk ratios for responder outcomes were estimated using modified Poisson regression.

Results

A total of 150 patients were included (ESG n=50; semaglutide n=100). Baseline age, sex, BMI, and metabolic comorbidities were comparable between groups. At 6 months, mean%TBWL was significantly higher with ESG than semaglutide (12.72±5.67% vs 8.67±3.84%; mean difference 4.05%; p=0.0001). After covariate adjustment, ESG remained superior (β=-4.04%; 95% CI -6.08 to -1.99; p=0.0001). IPTW analysis confirmed an adjusted mean difference of 4.20% favoring ESG (95% CI 2.12–6.28; p

Zitieren

APA

Jagtap, N., Aman, G., Katrevula, A., Shujaath, A., Reddy, D. N., & Kalapala, R. (2026). Endoscopic Sleeve Gastroplasty Versus Oral Semaglutide for Obesity: A Real-World Comparative Study. Endoscopy, 58(S 03 S 03), S96-S97. https://doi.org/10.1055/s-0046-1820792

Vancouver

Jagtap N, Aman G, Katrevula A, Shujaath A, Reddy DN, Kalapala R. Endoscopic Sleeve Gastroplasty Versus Oral Semaglutide for Obesity: A Real-World Comparative Study. Endoscopy. 2026;58(S 03 S 03):S96-S97. doi:10.1055/s-0046-1820792

BibTeX
@article{Jagtap2026,
  author = {Jagtap, N and Aman, G and Katrevula, A and Shujaath, A and Reddy, D N and Kalapala, R},
  title = {Endoscopic Sleeve Gastroplasty Versus Oral Semaglutide for Obesity: A Real-World Comparative Study},
  journal = {Endoscopy},
  year = {2026},
  volume = {58},
  number = {S 03 S 03},
  pages = {S96--S97},
  doi = {10.1055/s-0046-1820792}
}
Kostenlos starten →